FDA Rejects China-Developed Cancer Drug Ivonescimab for U.S. Market Approval
Trendline

FDA Rejects China-Developed Cancer Drug Ivonescimab for U.S. Market Approval

What's Happening? The U.S. Food and Drug Administration (FDA) has rejected the marketing approval application for Ivonescimab, a new cancer drug developed in China by Akeso Biopharma. Summit Therapeutics, the U.S. pharmaceutical company holding the rights to sell Ivonescimab in the United States, an
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.